Exicure Inc (XCUR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Exicure Inc (XCUR) has a cash flow conversion efficiency ratio of -0.544x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.14 Million) by net assets ($2.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Exicure Inc net asset quality index to measure how much of total assets are equity-financed.
Exicure Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Exicure Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Exicure Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Exicure Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Exicure Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rigsave S.P.A.
XETRA:H68
|
N/A |
|
GULLBERG+JANSSON AB
F:9D7
|
0.050x |
|
Inventure Growth & Securities Limited
NSE:INVENTURE
|
0.008x |
|
Erria A/S
CO:ERRIA
|
0.381x |
|
In8bio Inc
NASDAQ:INAB
|
-0.217x |
|
Globe Textiles (India) Limited
NSE:GLOBE
|
-0.089x |
|
REC Silicon ASA
OL:RECSI
|
0.174x |
|
Reliance Home Finance Limited
NSE:RHFL
|
-0.095x |
Annual Cash Flow Conversion Efficiency for Exicure Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Exicure Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see XCUR company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.93 Million | $-8.55 Million | -2.179x | -407.10% |
| 2024-12-31 | $6.77 Million | $-2.91 Million | -0.430x | +87.42% |
| 2023-12-31 | $3.03 Million | $-10.36 Million | -3.417x | -42.99% |
| 2022-12-31 | $14.92 Million | $-35.66 Million | -2.390x | +22.91% |
| 2021-12-31 | $11.23 Million | $-34.82 Million | -3.100x | -385.53% |
| 2020-12-31 | $61.51 Million | $-39.27 Million | -0.638x | -4014.57% |
| 2019-12-31 | $80.75 Million | $1.32 Million | 0.016x | +101.75% |
| 2018-12-31 | $20.95 Million | $-19.49 Million | -0.930x | +6.12% |
| 2017-12-31 | $19.98 Million | $-19.79 Million | -0.991x | +51.98% |
| 2016-12-31 | $2.45 Million | $-5.05 Million | -2.063x | -208.20% |
| 2015-12-31 | $18.23 Million | $-12.20 Million | -0.669x | -- |
About Exicure Inc
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood Ci… Read more